{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:28:05Z","timestamp":1758050885186,"version":"3.44.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cellimm.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T14:06:31Z","timestamp":1470319591000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV"],"prefix":"10.1016","volume":"310","author":[{"given":"Braira","family":"Wahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amjad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Idrees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazia","family":"Rafique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2016.08.001_b0005","series-title":"Allergy and Asthma Proceedings","article-title":"One hundred years of immunotherapy: review of the first landmark studies","author":"Larenas Linnemann","year":"2012"},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.mcna.2012.04.002","article-title":"Immunotherapies in infectious diseases","volume":"96","author":"Kak","year":"2012","journal-title":"Med. Clin. North Am."},{"year":"2002","series-title":"Immunotherapy for Infectious Diseases","author":"Jacobson","key":"10.1016\/j.cellimm.2016.08.001_b0015"},{"year":"2014","series-title":"Antimicrobial Resistance Global Report on Surveillance. 2014 Summary","author":"World Health Organization","key":"10.1016\/j.cellimm.2016.08.001_b0020"},{"issue":"6","key":"10.1016\/j.cellimm.2016.08.001_b0025","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tips.2004.04.002","article-title":"Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?","volume":"25","author":"Bayry","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"5073","key":"10.1016\/j.cellimm.2016.08.001_b0030","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1126\/science.257.5073.1050","article-title":"Epidemiology of drug resistance. Implications for a post-antimicrobial era","volume":"257","author":"Cohen","year":"1992","journal-title":"Science (Washington)"},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.mcna.2012.04.001","article-title":"Immunotherapy in clinical medicine: historical perspective and current status","volume":"96","author":"Shahani","year":"2012","journal-title":"Med. Clin. North Am."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0040","first-page":"21","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2567.2010.03330.x","article-title":"Immunoinformatics: an integrated scenario","volume":"131","author":"Tomar","year":"2010","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nm0303-269","article-title":"Immunotherapy: past, present and future","volume":"9","author":"Waldmann","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2016.08.001_b0060","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2016.08.001_b0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (Tfh)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2016.08.001_b0070","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.cellimm.2016.08.001_b0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri2569","article-title":"Signalling through C-type lectin receptors: shaping immune responses","volume":"9","author":"Geijtenbeek","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"5963","key":"10.1016\/j.cellimm.2016.08.001_b0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1184004","article-title":"How the noninflammasome NLRs function in the innate immune system","volume":"327","author":"Ting","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coi.2009.12.003","article-title":"Recognition of viruses by cytoplasmic sensors","volume":"22","author":"Wilkins","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0095","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cell.2006.02.019","article-title":"Translating innate immunity into immunological memory: implications for vaccine development","volume":"124","author":"Pulendran","year":"2006","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.immuni.2008.08.001","article-title":"Dendritic cells in vivo: a key target for a new vaccine science","volume":"29","author":"Steinman","year":"2008","journal-title":"Immunity"},{"issue":"6252","key":"10.1016\/j.cellimm.2016.08.001_b0105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/342877a0","article-title":"Conformations of immunoglobulin hypervariable regions","volume":"342","author":"Chothia","year":"1989","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.cellimm.2016.08.001_b0110","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","article-title":"Serum therapy revisited: animal models of infection and development of passive antibody therapy","volume":"38","author":"Casadevall","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3201\/eid0203.960306","article-title":"Antibody-based therapies for emerging infectious diseases","volume":"2","author":"Casadevall","year":"1996","journal-title":"Emerg. Infect. Dis."},{"issue":"2\u20133","key":"10.1016\/j.cellimm.2016.08.001_b0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1005948722912","article-title":"New aspects of immunotherapy of leptomeningeal metastasis","volume":"38","author":"Herrlinger","year":"1998","journal-title":"J. Neurooncol."},{"issue":"5447","key":"10.1016\/j.cellimm.2016.08.001_b0125","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1126\/science.286.5447.2156","article-title":"Control of early viral and bacterial distribution and disease by natural antibodies","volume":"286","author":"Ochsenbein","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0135","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3201\/eid0704.017432","article-title":"Treatment of West Nile virus encephalitis with intravenous immunoglobulin","volume":"7","author":"Shimoni","year":"2001","journal-title":"Emerg. Infect. Dis."},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1034\/j.1600-6143.2002.20505.x","article-title":"Treatment of Parvovirus B-19 (PV B-19) Infection Allows for Successful Kidney Transplantation Without Disease Recurrence","volume":"2","author":"Barsoum","year":"2002","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.cellimm.2016.08.001_b0145","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1086\/374666","article-title":"Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome","volume":"36","author":"Kerr","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.cellimm.2016.08.001_b0150","first-page":"1116","article-title":"Monoclonal antibodies for treating infectious diseases","volume":"25","author":"Klinguer-Hamour","year":"2009","journal-title":"Med. Sci."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nsmb.1574","article-title":"Universal epitopes of influenza virus hemagglutinins?","volume":"16","author":"Wang","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cellimm.2016.08.001_b0160","series-title":"mAbs","article-title":"Erratum to Motavizumab","author":"Cingoz","year":"2010"},{"issue":"10","key":"10.1016\/j.cellimm.2016.08.001_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000642","article-title":"A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection","volume":"5","author":"Bossart","year":"2009","journal-title":"PLoS Pathog"},{"issue":"105","key":"10.1016\/j.cellimm.2016.08.001_b0170","doi-asserted-by":"crossref","first-page":"105ra103","DOI":"10.1126\/scitranslmed.3002901","article-title":"A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge","volume":"3","author":"Bossart","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004717","article-title":"The ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases","volume":"11","author":"Casadevall","year":"2015","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/glycob\/8.2.121","article-title":"The role of site-specific N-glycosylation in secretion of soluble forms of rabies virus glycoprotein","volume":"8","author":"Wojczyk","year":"1998","journal-title":"Glycobiology"},{"issue":"15","key":"10.1016\/j.cellimm.2016.08.001_b0185","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1016\/S0021-9258(19)50073-4","article-title":"N-linked glycosylation of rabies virus glycoprotein. Individual sequons differ in their glycosylation efficiencies and influence on cell surface expression","volume":"267","author":"Shakin-Eshleman","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0190","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1371\/journal.pntd.0000243","article-title":"Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F (ab\u2032) 2 fragment rabies immunoglobulin (Favirab)","volume":"2","author":"Quiambao","year":"2008","journal-title":"PLoS Negl.Trop. Dis."},{"year":"2013","series-title":"WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans","author":"WHO","key":"10.1016\/j.cellimm.2016.08.001_b0195"},{"key":"10.1016\/j.cellimm.2016.08.001_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.01.016","article-title":"Benefits of using heterologous polyclonal antibodies and potential application to new and undertreated infectious pathogens","author":"Dixit","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.cellimm.2016.08.001_b0205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2217\/imt.14.40","article-title":"Specific polyclonal F (ab\u2032) 2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice","volume":"6","author":"Herbreteau","year":"2014","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.cellimm.2016.08.001_b0210","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.intimp.2011.08.011","article-title":"Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F (ab\u2032) 2 against highly pathogenic avian influenza H5N1 in mice","volume":"11","author":"Zhao","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4149\/av_2011_03_261","article-title":"Evaluation of anti-influenza efficiency of polyclonal IgG antibodies specific to the ectodomain of M2 protein of influenza A virus by passive immunization of mice","volume":"55","author":"Kiraly","year":"2010","journal-title":"Acta Virol."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0220","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(14)71072-2","article-title":"Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F (ab\u2032) 2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study","volume":"15","author":"Bal","year":"2015","journal-title":"Lancet. Infect. Dis"},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0225","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/JVI.78.2.834-840.2004","article-title":"Nipah virus: vaccination and passive protection studies in a hamster model","volume":"78","author":"Guillaume","year":"2004","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.cellimm.2016.08.001_b0230","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.cellimm.2016.08.001_b0235","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/JVI.75.10.4649-4654.2001","article-title":"Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication","volume":"75","author":"Gupta","year":"2001","journal-title":"J. Virol."},{"issue":"Supplement 1","key":"10.1016\/j.cellimm.2016.08.001_b0240","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/514310","article-title":"Evaluation of immune globulin and recombinant interferon-\u03b12b for treatment of experimental Ebola virus infections","volume":"179","author":"Jahrling","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0245","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.intimp.2006.10.009","article-title":"Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice","volume":"7","author":"Zhou","year":"2007","journal-title":"Int. Immunopharmacol."},{"issue":"4909","key":"10.1016\/j.cellimm.2016.08.001_b0250","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.2658060","article-title":"The role of somatic hypermutation in the generation of antibody diversity","volume":"244","author":"French","year":"1989","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.cellimm.2016.08.001_b0255","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1073\/pnas.89.15.6901","article-title":"Intracellular neutralization of virus by immunoglobulin A antibodies","volume":"89","author":"Mazanec","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"year":"2014","series-title":"Principles and Practice of Infectious Diseases","author":"Bennett","key":"10.1016\/j.cellimm.2016.08.001_b0260"},{"key":"10.1016\/j.cellimm.2016.08.001_b0265","series-title":"Prog. Allergy","first-page":"1","article-title":"Metabolism of Immunoglobulins (Part 1 of 3)","volume":"vol. 13","author":"Waldmann","year":"1969"},{"key":"10.1016\/j.cellimm.2016.08.001_b0270","series-title":"Seminars in Nuclear Medicine","article-title":"Immunologic and pharmacologic concepts of monoclonal antibodies","author":"Zuckier","year":"1989"},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0275","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199528020-00004","article-title":"Problems of delivery of monoclonal antibodies","volume":"28","author":"Reilly","year":"1995","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nec.2012.04.008","article-title":"Passive immunotherapeutic strategies for the treatment of malignant gliomas","volume":"23","author":"Nagasawa","year":"2012","journal-title":"Neurosurg. Clin. N. Am."},{"issue":"9","key":"10.1016\/j.cellimm.2016.08.001_b0285","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/imt.13.91","article-title":"CD4 T-cell immunotherapy for chronic viral infections and cancer","volume":"5","author":"Kamphorst","year":"2013","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0290","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/mr.57.1.183-289.1993","article-title":"Pathogenesis of human immunodeficiency virus infection","volume":"57","author":"Levy","year":"1993","journal-title":"Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0295","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.bmt.1705906","article-title":"Adoptive cellular immunotherapy for viral diseases","volume":"41","author":"Fujita","year":"2008","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0300","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.iy.13.040195.002553","article-title":"Principles for adoptive T cell therapy of human viral diseases","volume":"13","author":"Riddell","year":"1995","journal-title":"Annu. Rev. Immunol."},{"issue":"9939","key":"10.1016\/j.cellimm.2016.08.001_b0305","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"year":"2016","series-title":"Global Health Observatory (GHO) Data","author":"World Health Organization","key":"10.1016\/j.cellimm.2016.08.001_b0310"},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2009.10.007","article-title":"Current status and challenges of antiretroviral research and therapy","volume":"85","author":"Est\u00e9","year":"2010","journal-title":"Antiviral Res."},{"issue":"104","key":"10.1016\/j.cellimm.2016.08.001_b0320","first-page":"229","article-title":"An unexpected journey: how cancer immunotherapy has paved the way for an HIV-1 cure","volume":"19","author":"Smith","year":"2015","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0325","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.med.53.082901.104011","article-title":"Immunologic control of HIV-1","volume":"53","author":"Gandhi","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cellimm.2016.08.001_b0330","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.coviro.2016.02.010","article-title":"Approaches to preventative and therapeutic HIV vaccines","volume":"17","author":"Gray","year":"2016","journal-title":"Curr. Opin. Virol."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0335","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7774\/cevr.2016.5.1.6","article-title":"Recent update in HIV vaccine development","volume":"5","author":"Shin","year":"2016","journal-title":"Clin. Exp. Vac. Res."},{"issue":"11","key":"10.1016\/j.cellimm.2016.08.001_b0340","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1089\/aid.2012.0103","article-title":"The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120","volume":"28","author":"Karasavvas","year":"2012","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"12","key":"10.1016\/j.cellimm.2016.08.001_b0345","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0350","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/173.2.340","article-title":"Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1","volume":"173","author":"Mascola","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"25","key":"10.1016\/j.cellimm.2016.08.001_b0355","doi-asserted-by":"crossref","first-page":"9022","DOI":"10.1073\/pnas.1407877111","article-title":"Redemption of autoreactive B cells","volume":"111","author":"Haynes","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0360","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/428405","article-title":"Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial","volume":"191","author":"Gilbert","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.cellimm.2016.08.001_b0365","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.3390\/v6103968","article-title":"Challenges in the design of a T cell vaccine in the context of HIV-1 diversity","volume":"6","author":"Tongo","year":"2014","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.cellimm.2016.08.001_b0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020479","article-title":"Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cellimm.2016.08.001_b0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS One"},{"issue":"81","key":"10.1016\/j.cellimm.2016.08.001_b0380","doi-asserted-by":"crossref","first-page":"81ra36","DOI":"10.1126\/scitranslmed.3002351","article-title":"Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys","volume":"3","author":"Letvin","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.cellimm.2016.08.001_b0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021225","article-title":"A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)","volume":"6","author":"Churchyard","year":"2011","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.cellimm.2016.08.001_b0390","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"S1","key":"10.1016\/j.cellimm.2016.08.001_b0395","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1089\/aid.2014.5052a.abstract","article-title":"HVTN 097: evaluation of the RV144 vaccine regimen in HIV uninfected South African adults","volume":"30","author":"Gray","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0400","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1080\/21645515.2015.1010970","article-title":"Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection","volume":"11","author":"Vasan","year":"2015","journal-title":"Human Vac. Immunotherapeut."},{"issue":"310","key":"10.1016\/j.cellimm.2016.08.001_b0405","doi-asserted-by":"crossref","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2016.08.001_b0410","article-title":"Review of efficacy trials of HIV-1\/AIDS vaccines and regulatory lessons learned: a review from a regulatory perspective","author":"Sheets","year":"2015","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-015-0151-y","article-title":"HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial","volume":"12","author":"Ensoli","year":"2015","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-016-0261-1","article-title":"HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial","volume":"13","author":"Ensoli","year":"2016","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0425","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/aid.1995.11.257","article-title":"Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects","volume":"11","author":"Lieberman","year":"1995","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"8","key":"10.1016\/j.cellimm.2016.08.001_b0430","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mt.2015.102","article-title":"HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells","volume":"23","author":"Zhen","year":"2015","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.cellimm.2016.08.001_b0435","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/JVI.00474-15","article-title":"Novel CD4-based bispecific chimeric antigen receptor designed for enhanced Anti-HIV potency and absence of HIV entry receptor activity","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.cellimm.2016.08.001_b0440","series-title":"Seminars in Virology","article-title":"Cytokines and HIV infection","author":"Shearer","year":"1994"},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0445","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/095632020101200301","article-title":"Cytokines and HIV-1: interactions and clinical implications","volume":"12","author":"Kedzierska","year":"2001","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.cellimm.2016.08.001_b0450","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1097\/00002030-200100005-00022","article-title":"Cytokine-based therapies for HIV infection","volume":"15","author":"Allende","year":"2001","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0455","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cytogfr.2012.05.007","article-title":"The role of cytokines in the pathogenesis and treatment of HIV infection","volume":"23","author":"Catalfamo","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"issue":"23","key":"10.1016\/j.cellimm.2016.08.001_b0460","doi-asserted-by":"crossref","first-page":"10632","DOI":"10.1073\/pnas.1000027107","article-title":"In vivo expansion of naive and activated CD4+ CD25+ FOXP3+ regulatory T cell populations in interleukin-2\u2013treated HIV patients","volume":"107","author":"Weiss","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.cellimm.2016.08.001_b0465","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1089\/aid.2007.0047","article-title":"Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study","volume":"23","author":"Goujard","year":"2007","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0470","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002030-200302140-00008","article-title":"Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial","volume":"17","author":"Levy","year":"2003","journal-title":"AIDS"},{"issue":"25","key":"10.1016\/j.cellimm.2016.08.001_b0475","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1182\/blood-2008-10-186601","article-title":"IL-7 administration drives T cell\u2013cycle entry and expansion in HIV-1 infection","volume":"113","author":"Sereti","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0480","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/clim.2001.5111","article-title":"Decreased interferon-\u03b1 production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors","volume":"101","author":"Feldman","year":"2001","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0485","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V98.4.906","article-title":"Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients","volume":"98","author":"Soumelis","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0490","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00042560-199904010-00006","article-title":"Active anti-interferon-\u03b1 immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study)","volume":"20","author":"Gringeri","year":"1999","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"11","key":"10.1016\/j.cellimm.2016.08.001_b0495","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-112-11-805","article-title":"Interferon-\u03b1 in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized, placebo-controlled trial","volume":"112","author":"Lane","year":"1990","journal-title":"Ann. Intern. Med."},{"issue":"6151","key":"10.1016\/j.cellimm.2016.08.001_b0500","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.cellimm.2016.08.001_b0505","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Li","year":"2011","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003342","article-title":"Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans","volume":"9","author":"Julien","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cellimm.2016.08.001_b0515","doi-asserted-by":"crossref","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","author":"Caskey","year":"2015","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.cellimm.2016.08.001_b0520","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1073\/pnas.85.18.6939","article-title":"Monoclonal antibodies against human immunodeficiency virus (HIV) type 2 core proteins: cross-reactivity with HIV type 1 and simian immunodeficiency virus","volume":"85","author":"Minassian","year":"1988","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7427","key":"10.1016\/j.cellimm.2016.08.001_b0525","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.cellimm.2016.08.001_b0530","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1128\/JVI.00171-11","article-title":"An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum","volume":"85","author":"Ferrari","year":"2011","journal-title":"J. Virol."},{"issue":"7475","key":"10.1016\/j.cellimm.2016.08.001_b0535","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cellimm.2016.08.001_b0540","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0009-9236(96)90006-5","article-title":"Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1","volume":"59","author":"Wolfe","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6288","key":"10.1016\/j.cellimm.2016.08.001_b0545","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cellimm.2016.08.001_b0550","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10875-004-6250-5","article-title":"Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy","volume":"24","author":"Finke","year":"2004","journal-title":"J. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.cellimm.2016.08.001_b0555","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1147","article-title":"Therapeutic dendritic-cell vaccine for chronic HIV-1 infection","volume":"10","author":"Lu","year":"2004","journal-title":"Nat. Med."},{"issue":"166","key":"10.1016\/j.cellimm.2016.08.001_b0560","doi-asserted-by":"crossref","first-page":"166ra2","DOI":"10.1126\/scitranslmed.3004682","article-title":"A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication","volume":"5","author":"Garc\u00eda","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0565","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/infdis\/jiq077","article-title":"A therapeutic dendritic cell-based vaccine for HIV-1 infection","volume":"203","author":"Garc\u00eda","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0570","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jmv.21376","article-title":"Retracted: Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF)","volume":"81","author":"Yamamoto","year":"2009","journal-title":"J. Med. Virol."},{"year":"2001","series-title":"Human Papillomavirus: A Hidden Epidemic in the United States","author":"Creel","key":"10.1016\/j.cellimm.2016.08.001_b0575"},{"issue":"12","key":"10.1016\/j.cellimm.2016.08.001_b0580","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.cellimm.2016.08.001_b0585","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/507432","article-title":"Prevalence of HPV infection among men: a systematic review of the literature","volume":"194","author":"Dunne","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"25","key":"10.1016\/j.cellimm.2016.08.001_b0590","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa053284","article-title":"Condom use and the risk of genital human papillomavirus infection in young women","volume":"354","author":"Winer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2016.08.001_b0595","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"The burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.cellimm.2016.08.001_b0600","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1002\/eji.201444594","article-title":"Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer","volume":"44","author":"Langers","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"29","key":"10.1016\/j.cellimm.2016.08.001_b0605","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.vaccine.2015.05.016","article-title":"Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2","volume":"33","author":"Tumban","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.cellimm.2016.08.001_b0610","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0615","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14712598.8.4.421","article-title":"Therapeutic human papillomavirus vaccines: current clinical trials and future directions","volume":"8","author":"Hung","year":"2008","journal-title":"Exp. Opin. Biol. Ther."},{"key":"10.1016\/j.cellimm.2016.08.001_b0620","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0625","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/S1470-2045(14)71191-X","article-title":"FDA approves new upgraded Gardasil 9","volume":"16","author":"Kirby","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cellimm.2016.08.001_b0630","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2016.03.016","article-title":"Gardasil-9: a global survey of projected efficacy","volume":"130","author":"Zhai","year":"2016","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.cellimm.2016.08.001_b0635","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1586\/14760584.2015.1051470","article-title":"Gardasil 9 joins the fight against cervix cancer","volume":"14","author":"Cuzick","year":"2015","journal-title":"Exp. Rev. Vac."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0640","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"De Villiers","year":"2004","journal-title":"Virology"},{"issue":"9580","key":"10.1016\/j.cellimm.2016.08.001_b0645","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cellimm.2016.08.001_b0650","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1586\/14737140.7.10.1473","article-title":"Advances in dendritic cell-based therapeutic vaccines for cervical cancer","volume":"7","author":"Bellone","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0655","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2005.09.040","article-title":"HPV16\/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities","volume":"100","author":"Santin","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"5 Suppl","key":"10.1016\/j.cellimm.2016.08.001_b0660","article-title":"ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer","volume":"32","author":"Basu","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.cellimm.2016.08.001_b0665","doi-asserted-by":"crossref","first-page":"P426","DOI":"10.1186\/2051-1426-3-S2-P426","article-title":"Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids)+ INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results","volume":"3","author":"Aggarwal","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"10008","key":"10.1016\/j.cellimm.2016.08.001_b0670","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cellimm.2016.08.001_b0675","first-page":"1","article-title":"Current state in the development of candidate therapeutic HPV vaccines","author":"Yang","year":"2016","journal-title":"Expert Rev. Vac."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0680","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1473-3099(01)00095-0","article-title":"Topical immunomodulators\u2014progress towards treating inflammation, infection, and cancer","volume":"1","author":"Hengge","year":"2001","journal-title":"Lancet. Infect. Dis"},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0685","first-page":"1078","article-title":"ADXS-HPV immunotherapy promising for anal cancer","volume":"11","author":"Brtnikova","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"Suppl. 1","key":"10.1016\/j.cellimm.2016.08.001_b0690","article-title":"PD-1 and PD-L1 expression in 1599 gynecological malignancies-implications for immunotherapy","volume":"137","author":"Herzog","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.cellimm.2016.08.001_b0695","doi-asserted-by":"crossref","first-page":"P152","DOI":"10.1186\/2051-1426-3-S2-P152","article-title":"Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab+ tremelimumab, in patients with recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN)","volume":"3","author":"Gilbert","year":"2015","journal-title":"CONDOR J. Immunother. Cancer"},{"key":"10.1016\/j.cellimm.2016.08.001_b0700","series-title":"ASCO Annual Meeting Proceedings","article-title":"A phase 1\/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: a study of the Princess Margaret and Chicago N01 Consortia","author":"Lheureux","year":"2014"},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0705","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1556\/EuJMI.4.2014.1.5","article-title":"Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs","volume":"4","author":"Vidyasagar","year":"2014","journal-title":"Eur. J. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1746-1596-9-101","article-title":"Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein","volume":"9","author":"Wang","year":"2014","journal-title":"Diagn. Pathol."},{"issue":"7","key":"10.1016\/j.cellimm.2016.08.001_b0715","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.cellimm.2016.08.001_b0720","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2016.08.001_b0725","series-title":"ASCO Annual Meeting Proceedings","article-title":"A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors","author":"Lassen","year":"2015"},{"issue":"8","key":"10.1016\/j.cellimm.2016.08.001_b0730","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2326-6066.CIR-14-0119","article-title":"Cancer immunotherapy highlights from the 2014 ASCO meeting","volume":"2","author":"Harshman","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0735","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/156800908784293596","article-title":"Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours","volume":"8","author":"Bubenik","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"14","key":"10.1016\/j.cellimm.2016.08.001_b0740","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1200\/JCO.2014.60.6566","article-title":"Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer","volume":"33","author":"Zsiros","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0745","article-title":"Proportion of herpes simplex virus (HSV) type 1 and type 2 among genital and extragenital HSV isolates","volume":"82","author":"L\u00f6whagen","year":"2002","journal-title":"Acta Dermato-Venereol."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0750","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/iai.12.1.76-80.1975","article-title":"Depressed specific cell-mediated immunity to Herpes simplex virus type 1 in patients with recurrent herpes labialis","volume":"12","author":"Thong","year":"1975","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0755","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1099-1654(200005\/06)10:3<141::AID-RMV280>3.0.CO;2-2","article-title":"HSV-2 specific serology should be offered routinely to antenatal patients","volume":"10","author":"Brown","year":"2000","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.17.1.1-13.2004","article-title":"Neonatal herpes simplex infection","volume":"17","author":"Kimberlin","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0765","first-page":"87","article-title":"Herpes simplex virus","volume":"25","author":"Fountain","year":"2004","journal-title":"Pediatr. Rev."},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0770","first-page":"310","article-title":"Treatment of Herpes simplex virus infections with topical antiviral agents","volume":"8","author":"Hamuy","year":"1997","journal-title":"Eur. J. Dermatol."},{"year":"2007","author":"Kimberlin","key":"10.1016\/j.cellimm.2016.08.001_b0775"},{"issue":"18","key":"10.1016\/j.cellimm.2016.08.001_b0780","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/00002030-200212060-00007","article-title":"Association between cervical shedding of herpes simplex virus and HIV-1","volume":"16","author":"McClelland","year":"2002","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0785","first-page":"437","article-title":"Herpes simplex virus type 2 vaccines: new ground for optimism?","volume":"11","author":"Aurelian","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"2","key":"10.1016\/j.cellimm.2016.08.001_b0790","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1099\/0022-1317-79-2-353","article-title":"Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes","volume":"79","author":"Mikloska","year":"1998","journal-title":"J. Gen. Virol."},{"issue":"21","key":"10.1016\/j.cellimm.2016.08.001_b0795","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D\u2013adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0800","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/v8040110","article-title":"Vaccination with the secreted glycoprotein G of herpes simplex virus 2 induces protective immunity after genital infection","volume":"8","author":"\u00d6nnheim","year":"2016","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0805","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0166-3542(89)90005-3","article-title":"Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy","volume":"11","author":"Stanberry","year":"1989","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0810","doi-asserted-by":"crossref","DOI":"10.1038\/sj.gt.3301620","article-title":"The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma","volume":"9","author":"Chung","year":"2002","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.cellimm.2016.08.001_b0815","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1128\/iai.12.6.1258-1261.1975","article-title":"Passive immunization in experimental Herpesvirus hominis infection of newborn mice","volume":"12","author":"Luyet","year":"1975","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.cellimm.2016.08.001_b0820","first-page":"446","article-title":"Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells","volume":"27","author":"Oleske","year":"1977","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0825","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1128\/iai.34.1.192-199.1981","article-title":"Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease","volume":"34","author":"Dix","year":"1981","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0830","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/02713688709020086","article-title":"Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease","volume":"6","author":"Metcalf","year":"1987","journal-title":"Curr. Eye Res."},{"issue":"1","key":"10.1016\/j.cellimm.2016.08.001_b0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116800","article-title":"Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody","volume":"10","author":"Krawczyk","year":"2015","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.cellimm.2016.08.001_b0840","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1073\/pnas.1220019110","article-title":"Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody","volume":"110","author":"Krawczyk","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.cellimm.2016.08.001_b0845","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1099\/0022-1317-68-11-2831","article-title":"Augmentation of natural immune defence mechanisms and therapeutic potential of a mismatched double-stranded polynucleotide in cutaneous herpes simplex virus type 2 infection","volume":"68","author":"Aurelian","year":"1987","journal-title":"J. Gen. Virol."},{"issue":"12","key":"10.1016\/j.cellimm.2016.08.001_b0850","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.4049\/jimmunol.160.12.6093","article-title":"T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2","volume":"160","author":"Milligan","year":"1998","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cellimm.2016.08.001_b0855","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/infdis\/169.4.787","article-title":"Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein","volume":"169","author":"Nakao","year":"1994","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.cellimm.2016.08.001_b0860","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1128\/jvi.68.5.2803-2810.1994","article-title":"Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions","volume":"68","author":"Koelle","year":"1994","journal-title":"J. Virol."},{"issue":"Supplement 11","key":"10.1016\/j.cellimm.2016.08.001_b0865","doi-asserted-by":"crossref","first-page":"S924","DOI":"10.1093\/clind\/13.Supplement_11.S924","article-title":"Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D","volume":"13","author":"Aurelian","year":"1991","journal-title":"Rev. Infect. Dis."},{"year":"2007","series-title":"Human herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"Arvin","key":"10.1016\/j.cellimm.2016.08.001_b0870"}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874916300648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874916300648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:54:42Z","timestamp":1757804082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874916300648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":174,"alternative-id":["S0008874916300648"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2016.08.001","relation":{},"ISSN":["0008-8749"],"issn-type":[{"type":"print","value":"0008-8749"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}